Marcos Hazday, MD
Cardiovascular Disease · Celebration, FLNPI 1669434809
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,780 of the $14,351 with a category attached, or 61.2%. 28 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 28.5% of the total. Reporting peaked in 2022 at $7,461 and has fallen 92.0% since, to $594 in 2025.
Across 293 payments — averaging $48.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Pfizer$4K
- Medtronic$2K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$811
- Abbott$350
- plus $2K from 22 others
Across 5 payments — averaging $7403.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lexicon Pharmaceuticals, Inc.$37K
What the payments were for
- Speaking & faculty fees$8,78061%
- Travel & lodging$180%
- Food & beverage$4,95635%
- Education$5974%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 32 | $4,087 |
| Pfizer | 31 | $3,809 |
| Medtronic(2 entities) | 6 | $2,207 |
| Johnson & Johnson | 134 | $1,353 |
| Astellas Pharma US Inc | 14 | $811 |
| Abbott | 9 | $350 |
| Amgen | 15 | $290 |
| Biotronik Inc. | 2 | $269 |
| Atricure, Inc. | 6 | $121 |
| Merck | 6 | $120 |
| Novartis | 6 | $119 |
| Cvrx, Inc. | 2 | $98 |
| Kestra Medical Technology Services, Inc. | 3 | $96 |
| Artivion, Inc. | 1 | $87 |
| Irhythm Technologies, Inc. | 2 | $84 |
| Boehringer Ingelheim | 3 | $76 |
| Alnylam Pharmaceuticals Inc. | 3 | $74 |
| AstraZeneca | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Impulse Dynamics (USA) Inc. | 2 | $41 |
| Bardy Diagnostics, Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Bayer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$3,763
- VYNDAQEL$3,325
- Acticor 7 VR-T DX$149
- XARELTO$124
- BioMonitor$120
- Repatha$110
- CARDIOMEMS$102
- Evera$100
How this compares
$14,351 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 104 | $838,070 |
| EliquisApixaban | 151 | $177,724 |
| JardianceEmpagliflozin | 67 | $57,847 |
| Repatha SureclickEvolocumab | 44 | $42,420 |
| EntrestoSacubitril/Valsartan | 24 | $35,148 |
| XareltoRivaroxaban | 27 | $27,105 |
| Nebivolol Hcl | 30 | $2,534 |
| Metoprolol Succinate | 126 | $2,129 |
| Rosuvastatin Calcium | 109 | $2,038 |
| Ranolazine ErRanolazine | 18 | $1,266 |
| Valsartan | 35 | $1,197 |
| Ezetimibe | 49 | $1,126 |
| Bisoprolol Fumarate | 44 | $930 |
| Olmesartan Medoxomil | 49 | $855 |
| Carvedilol | 55 | $787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $4,087 | $838,070104 claims |
| PfizerEliquis | $3,809 | $177,724151 claims |
| Boehringer IngelheimJardiance | $76 | $57,84767 claims |
| NovartisEntresto | $119 | $35,14824 claims |
| Johnson & JohnsonXarelto | $1,353 | $27,10527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Celebration
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.